SPECIAL FEATURES

1347 Introducing New Strategies in…
James L. Abbruzzese, Alexander M.M. Eggermont, and Eric H. Rubin

1348 New Strategies in Kidney Cancer: Therapeutic Advances through Understanding the Molecular Basis of Response and Resistance
Brian I. Rini

1355 Does Lapatinib Work against HER2-negative Breast Cancers?
Ingrid A. Mayer and Carlos L. Arteaga
See article p. 1486

1358 Testing Clonal Relatedness of Tumors Using Array Comparative Genomic Hybridization: A Statistical Challenge
Irina Ostrovnaya and Colin B. Begg

1368 Everolimus
Peter J. Houghton

1373 HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy
Marcia R. Campbell, Dhara Amin, and Mark M. Moasser

1384 Cyclooxygenase-2 and Cancer Treatment: Understanding the Risk Should Be Worth the Reward
David G. Menter, Richard L. Schilsky, and Raymond N. DuBois

HUMAN CANCER BIOLOGY

1391 High-Resolution Array Comparative Genomic Hybridization in Sporadic and Celiac Disease–Related Small Bowel Adenocarcinomas
Begoña Diosdado, Tineke E. Buffart, Russell Watkins, Beatriz Carvalho, Bauke Ylstra, Marianne Tijssen, Anne S. Bolijn, Fraser Lewis, Karen Maude, Caroline Verbeke, Iris D. Nagtegaal, Heike Grabsch, Chris J.J. Mulder, Phil Quirke, Peter Howdle, and Gerrit A. Meijer

1402 Critical Role of Ge1,13 and Ge13 for Human Small Cell Lung Cancer Cell Proliferation In vitro and Tumor Growth In vivo
Marius Grzelinski, Olaf Pinkenburg, Thomas Büch, Maike Gold, Stefanie Stohr, Hermann Kalwa, Thomas Gudermann, and Achim Aigner

1416 Association of TGF-β1 Genetic Variants with HPV16-positive Oropharyngeal Cancer
Xiaoxiang Guan, Erich M. Sturgis, Dapeng Lei, Zhengsheng Liu, Kristina R. Dahlstrom, Qingyi Wei, and Guojun Li

1423 ZIP4 Regulates Pancreatic Cancer Cell Growth by Activating IL-6/STAT3 Pathway through Zinc Finger Transcription Factor CREB
Yuqing Zhang, Uddalak Bharadwaj, Craig D. Logsdon, Changyi Chen, Qizhi Yao, and Min Li

1431 Neuroblastoma Progression Correlates with Downregulation of the Lymphangiogenesis Inhibitor sVEGFR-2
Jürgen Becker, Helena Pavlakovic, Fabian Ludewig, Fabiola Wilting, Herbert A. Weich, Romulo Albuquerque, Jayakrishna Ambati, and Jörg Wilting
### CANCER THERAPY: PRECLINICAL

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1442</td>
<td>Patient-Derived First Generation Xenografts of Non–Small Cell Lung Cancers: Promising Tools for Predicting Drug Responses for Personalized Chemotherapy</td>
<td>Xin Dong, Jun Guan, John C. English, Julia Flint, John Yee, Kenneth Evans, Nevin Murray, Calum MacAulay, Raymond T. Ng, Peter W. Gout, Wan L. Lam, Janessa Laskin, Victor Ling, Stephen Lam, and Yuzhuo Wang</td>
</tr>
<tr>
<td>1452</td>
<td>Comparative Profiling of the Novel Epothilone, Sagopilone, in Xenografts Derived from Primary Non–Small Cell Lung Cancer</td>
<td>Stefanie Hammer, Anette Sommer, Iduna Fichtner, Michael Becker, Jana Rolff, Johannes Merk, Ulrich Klar, and Jens Hoffmann</td>
</tr>
<tr>
<td>1466</td>
<td>An Adenoviral Vaccine Encoding Full-Length Inactivated Human Her2 Exhibits Potent Immunogenicity and Enhanced Therapeutic Efficacy without Oncogenicity</td>
<td>Zachary Hartman, Junping Wei, Takuya Osada, Oliver Glass, Gangjun Lei, Xiao-Yi Yang, Sharon Peplinski, Dong-Wan Kim, Wenle Xia, Neil Specter, Jeffrey Marks, William Barry, Amy Hobeika, Gayathri Devi, Andrea Amalfitano, Michael A. Morse, H. Kim Lyerly, and Timothy M. Clay</td>
</tr>
<tr>
<td>1478</td>
<td>Lestaurtinib Enhances the Antitumor Efficacy of Chemotherapy in Murine Xenograft Models of Neuroblastoma</td>
<td>Radhika Iyer, Audrey E. Evans, Xiaoxue Qi, Ruth Ho, Jane E. Minturn, Huaqing Zhao, Naomi Balamuth, John M. Maris, and Garrett M. Brodeur</td>
</tr>
<tr>
<td>1498</td>
<td>Preclinical Investigation of PEGylated Tumor Necrosis Factor α in Dogs with Spontaneous Tumors: Phase 1 Evaluation</td>
<td>Douglas H. Thamm, Ilene D. Kurzman, Mike A. Clark, E.J. Ehrhart III, Susan L. Kraft, Daniel L. Gustafson, and David M. Vail</td>
</tr>
</tbody>
</table>

### IMAGING, DIAGNOSIS, PROGNOSIS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1509</td>
<td>Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo</td>
<td>Zev A. Wainberg, Adrian Anghel, Amrita J. Desai, Raoul Ayala, Tong Luo, Brent Safran, Marlena S. Fejzo, J. Randolph Hecht, Dennis J. Slamon, and Richard S. Finn</td>
</tr>
<tr>
<td>1520</td>
<td>Defucosylated Humanized Anti-CCR4 Monoclonal Antibody KW-0761 as a Novel Immunotherapeutic Agent for Adult T-cell Leukemia/Lymphoma</td>
<td>Toshihiko Ishii, Takashi Ishida, Atae Utsunomiya, Atsushi Inagaki, Hiroki Yano, Hirokazu Komatsu, Shinsuke Iida, Kazunori Imada, Takashi Uchiyama, Shiro Akinaga, Kenya Shitara, and Ryuzo Ueda</td>
</tr>
<tr>
<td>1532</td>
<td>Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature</td>
<td>Kateleen De Preter, Joëlle Vermeulen, Benedikt Brors, Olivier Delattre, Angelika Egger, Matthias Fischer, Isabelle Janoueix-Lerosey, Cinzia Lavarno, John M. Maris, JAume Mora, Akira Nakagawara, André Obert, Miki Ohira, Gudrun Schleiermacher, Alexander Schramm, Johannes H. Schulte, Qun Wang, Frank Westermann, Frank Speleman, and Jo Vandesompele</td>
</tr>
<tr>
<td>1553</td>
<td>Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer</td>
<td>Sarah Minner, Birte Jessen, Lars Stiedenroth, Eike Burandt, Jens Köllermann, Martina Mirlacher, Andreas Erbersdobler, Christian Eichelberg, Margit Fischer, Tim Henrik Brümmendorf, Carsten Bokemeyer, Ronald Simon, Thomas Steuber, Markus Graefen, Hartwig Huland, Guido Sauter, and Thorsten Schlomm</td>
</tr>
</tbody>
</table>
A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry

Evaluation of the ETS-Related Gene mRNA in Urine for the Detection of Prostate Cancer

Melanoma MicroRNA Signature Predicts Post-Recurrence Survival

Development of Immunohistochemistry Assays to Assess GALNT14 and FUT3/6 in Clinical Trials of Dulanermin and Drozitumab
Howard M. Stern, Mary Padilla, Klaus Wagner, Lukas Amler, and Avi Ashkenazi

IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendrogial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
Martin J. van den Bent, Hendrikus J. Dubbink, Yannick Marie, Alba A. Brandes, Martin J.B. Taphoorn, Pieter Wesseling, Marc Frenay, Coen C. Tijsen, Denis Lacombe, Ahmed Idsahil, Ronald van Marion, Johan M. Kros, Winand N.M. Dinjens, Thierry Gorlia, and Marc Sanson

Cyclooxygenase-2 Inhibition Does Not Improve the Reduction in Ductal Carcinoma In situ Proliferation with Aromatase Inhibitor Therapy: Results of the ERISAC Randomized Placebo-Controlled Trial

The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

Estrogen Receptor-α Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer
Josefine Becker, Lambert Skoog, Tommy Fonander, Bo Nordenskjöld, and Olle Stål

A Phase II Clinical Trial of Ixabepilone (Ixempra; BMS-247550; NSC 710428), an Epothilone B Analog, in Patients with Metastatic Renal Cell Carcinoma
Hui Huang, Michael Menefee, Maureen Edgerly, Sen Zhuang, Herb Kotz, Marianne Poruchynsky, Lyn Mickley Huff, Susan Bates, and Tito Fojo

Diverse Patterns of T-Cell Response against Multiple Newly Identified Human Y Chromosome–Encoded Minor Histocompatibility Epitopes
Yishai Ofran, Haesook T. Kim, Vladimir Brusic, Loren Blake, Michael Mandrell, Catherine J. Wu, Stefanie Sarantopoulos, Roberto Bellucci, Derin B. Keskin, Robert J. Soiffer, Joseph H. Antin, and Jerome Ritz
The featured image is a lung adenocarcinoma stained with a novel, highly sensitive and specific antibody recognizing the ALK oncoprotein (brown staining) and counterstained with hematoxylin (blue staining). The tumor was shown to harbor a rearrangement of the ALK locus by genetic analysis. This assay will facilitate the routine identification of ALK-rearranged lung adenocarcinomas in clinical practice and detect lung cancers that may be responsive to ALK inhibitors. For details, see the article by Mino-Kenudson and colleagues on page 1561 of this issue.